Cargando…

IMM‐H007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high‐fat diet

Nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disease in humans, is characterized by the accumulation of triacylglycerols (TGs) in hepatocytes. We tested whether 2′,3′,5′‐tri‐acetyl‐N6‐(3‐hydroxylaniline) adenosine (IMM‐H007) can eliminate hepatic steatosis in hamsters fed...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Huijie, Wang, Qingchun, Yang, Liu, Xie, Shouxia, Zhu, Haibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586352/
https://www.ncbi.nlm.nih.gov/pubmed/28904866
http://dx.doi.org/10.1002/2211-5463.12272
_version_ 1783261802017062912
author Shi, Huijie
Wang, Qingchun
Yang, Liu
Xie, Shouxia
Zhu, Haibo
author_facet Shi, Huijie
Wang, Qingchun
Yang, Liu
Xie, Shouxia
Zhu, Haibo
author_sort Shi, Huijie
collection PubMed
description Nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disease in humans, is characterized by the accumulation of triacylglycerols (TGs) in hepatocytes. We tested whether 2′,3′,5′‐tri‐acetyl‐N6‐(3‐hydroxylaniline) adenosine (IMM‐H007) can eliminate hepatic steatosis in hamsters fed a high‐fat diet (HFD), as a model of NAFLD. Compared with HFD‐only controls, IMM‐H007 treatment significantly lowered serum levels of TG, total cholesterol, and free fatty acids (FFAs) in hamsters fed the HFD, with a prominent decrease in levels of serum transaminases and fasting insulin, without affecting fasting glucose levels. Moreover, (1)H‐MRI and histopathological analyses revealed that hepatic lipid accumulation and fibrosis were improved by IMM‐H007 treatment. These changes were accompanied by improvement of insulin resistance and oxidative stress, and attenuation of inflammation. IMM‐H007 reduced expression of proteins involved in uptake of hepatic fatty acids and lipogenesis, and increased very low density lipoprotein secretion and expression of proteins responsible for fatty acid oxidation and autophagy. In studies in vivo, IMM‐H007 inhibited fatty acid import into hepatocytes and liver lipogenesis, and concomitantly stimulated fatty acid oxidation, autophagy, and export of hepatic lipids. These data suggest that IMM‐H007 resolves hepatic steatosis in HFD‐fed hamsters by the regulation of lipid metabolism. Thus, IMM‐H007 has therapeutic potential for NAFLD.
format Online
Article
Text
id pubmed-5586352
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55863522017-09-13 IMM‐H007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high‐fat diet Shi, Huijie Wang, Qingchun Yang, Liu Xie, Shouxia Zhu, Haibo FEBS Open Bio Research Articles Nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disease in humans, is characterized by the accumulation of triacylglycerols (TGs) in hepatocytes. We tested whether 2′,3′,5′‐tri‐acetyl‐N6‐(3‐hydroxylaniline) adenosine (IMM‐H007) can eliminate hepatic steatosis in hamsters fed a high‐fat diet (HFD), as a model of NAFLD. Compared with HFD‐only controls, IMM‐H007 treatment significantly lowered serum levels of TG, total cholesterol, and free fatty acids (FFAs) in hamsters fed the HFD, with a prominent decrease in levels of serum transaminases and fasting insulin, without affecting fasting glucose levels. Moreover, (1)H‐MRI and histopathological analyses revealed that hepatic lipid accumulation and fibrosis were improved by IMM‐H007 treatment. These changes were accompanied by improvement of insulin resistance and oxidative stress, and attenuation of inflammation. IMM‐H007 reduced expression of proteins involved in uptake of hepatic fatty acids and lipogenesis, and increased very low density lipoprotein secretion and expression of proteins responsible for fatty acid oxidation and autophagy. In studies in vivo, IMM‐H007 inhibited fatty acid import into hepatocytes and liver lipogenesis, and concomitantly stimulated fatty acid oxidation, autophagy, and export of hepatic lipids. These data suggest that IMM‐H007 resolves hepatic steatosis in HFD‐fed hamsters by the regulation of lipid metabolism. Thus, IMM‐H007 has therapeutic potential for NAFLD. John Wiley and Sons Inc. 2017-08-29 /pmc/articles/PMC5586352/ /pubmed/28904866 http://dx.doi.org/10.1002/2211-5463.12272 Text en © 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Shi, Huijie
Wang, Qingchun
Yang, Liu
Xie, Shouxia
Zhu, Haibo
IMM‐H007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high‐fat diet
title IMM‐H007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high‐fat diet
title_full IMM‐H007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high‐fat diet
title_fullStr IMM‐H007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high‐fat diet
title_full_unstemmed IMM‐H007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high‐fat diet
title_short IMM‐H007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high‐fat diet
title_sort imm‐h007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high‐fat diet
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586352/
https://www.ncbi.nlm.nih.gov/pubmed/28904866
http://dx.doi.org/10.1002/2211-5463.12272
work_keys_str_mv AT shihuijie immh007anewtherapeuticcandidatefornonalcoholicfattyliverdiseaseimproveshepaticsteatosisinhamstersfedahighfatdiet
AT wangqingchun immh007anewtherapeuticcandidatefornonalcoholicfattyliverdiseaseimproveshepaticsteatosisinhamstersfedahighfatdiet
AT yangliu immh007anewtherapeuticcandidatefornonalcoholicfattyliverdiseaseimproveshepaticsteatosisinhamstersfedahighfatdiet
AT xieshouxia immh007anewtherapeuticcandidatefornonalcoholicfattyliverdiseaseimproveshepaticsteatosisinhamstersfedahighfatdiet
AT zhuhaibo immh007anewtherapeuticcandidatefornonalcoholicfattyliverdiseaseimproveshepaticsteatosisinhamstersfedahighfatdiet